Cargando…
Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer
In health technology assessment, decisions are based on complex cost-effectiveness models that require numerous input parameters. When not all relevant estimates are available, the model may have to be simplified. Multiparameter evidence synthesis combines data from diverse sources of evidence, whic...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156771/ https://www.ncbi.nlm.nih.gov/pubmed/30102868 http://dx.doi.org/10.1177/0272989X18788537 |
_version_ | 1783358161289216000 |
---|---|
author | Tan, Sze Huey Abrams, Keith R. Bujkiewicz, Sylwia |
author_facet | Tan, Sze Huey Abrams, Keith R. Bujkiewicz, Sylwia |
author_sort | Tan, Sze Huey |
collection | PubMed |
description | In health technology assessment, decisions are based on complex cost-effectiveness models that require numerous input parameters. When not all relevant estimates are available, the model may have to be simplified. Multiparameter evidence synthesis combines data from diverse sources of evidence, which results in obtaining estimates required in clinical decision making that otherwise may not be available. We demonstrate how bivariate meta-analysis can be used to predict an unreported estimate of a treatment effect enabling implementation of a multistate Markov model, which otherwise needs to be simplified. To illustrate this, we used an example of cost-effectiveness analysis for docetaxel in combination with prednisolone in metastatic hormone-refractory prostate cancer. Bivariate meta-analysis was used to model jointly available data on treatment effects on overall survival and progression-free survival (PFS) to predict the unreported effect on PFS in a study evaluating docetaxel with prednisolone. The predicted treatment effect on PFS enabled implementation of a 3-state Markov model comprising stable disease, progressive disease, and dead states, while lack of the estimate restricted the model to a 2-state model (with alive and dead states). The 2-state and 3-state models were compared by calculating the incremental cost-effectiveness ratio (which was much lower in the 3-state model: £22,148 per quality-adjusted life year gained compared to £30,026 obtained from the 2-state model) and the expected value of perfect information (which increased with the 3-state model). The 3-state model has the advantage of distinguishing surviving patients who progressed from those who did not progress. Hence, the use of advanced meta-analytic techniques allowed obtaining relevant parameter estimates to populate a model describing disease pathway in more detail while helping to prevent valuable clinical data from being discarded. |
format | Online Article Text |
id | pubmed-6156771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-61567712018-10-11 Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer Tan, Sze Huey Abrams, Keith R. Bujkiewicz, Sylwia Med Decis Making Original Articles In health technology assessment, decisions are based on complex cost-effectiveness models that require numerous input parameters. When not all relevant estimates are available, the model may have to be simplified. Multiparameter evidence synthesis combines data from diverse sources of evidence, which results in obtaining estimates required in clinical decision making that otherwise may not be available. We demonstrate how bivariate meta-analysis can be used to predict an unreported estimate of a treatment effect enabling implementation of a multistate Markov model, which otherwise needs to be simplified. To illustrate this, we used an example of cost-effectiveness analysis for docetaxel in combination with prednisolone in metastatic hormone-refractory prostate cancer. Bivariate meta-analysis was used to model jointly available data on treatment effects on overall survival and progression-free survival (PFS) to predict the unreported effect on PFS in a study evaluating docetaxel with prednisolone. The predicted treatment effect on PFS enabled implementation of a 3-state Markov model comprising stable disease, progressive disease, and dead states, while lack of the estimate restricted the model to a 2-state model (with alive and dead states). The 2-state and 3-state models were compared by calculating the incremental cost-effectiveness ratio (which was much lower in the 3-state model: £22,148 per quality-adjusted life year gained compared to £30,026 obtained from the 2-state model) and the expected value of perfect information (which increased with the 3-state model). The 3-state model has the advantage of distinguishing surviving patients who progressed from those who did not progress. Hence, the use of advanced meta-analytic techniques allowed obtaining relevant parameter estimates to populate a model describing disease pathway in more detail while helping to prevent valuable clinical data from being discarded. SAGE Publications 2018-08-13 2018-10 /pmc/articles/PMC6156771/ /pubmed/30102868 http://dx.doi.org/10.1177/0272989X18788537 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles Tan, Sze Huey Abrams, Keith R. Bujkiewicz, Sylwia Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer |
title | Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer |
title_full | Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer |
title_fullStr | Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer |
title_full_unstemmed | Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer |
title_short | Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer |
title_sort | bayesian multiparameter evidence synthesis to inform decision making: a case study in metastatic hormone-refractory prostate cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156771/ https://www.ncbi.nlm.nih.gov/pubmed/30102868 http://dx.doi.org/10.1177/0272989X18788537 |
work_keys_str_mv | AT tanszehuey bayesianmultiparameterevidencesynthesistoinformdecisionmakingacasestudyinmetastatichormonerefractoryprostatecancer AT abramskeithr bayesianmultiparameterevidencesynthesistoinformdecisionmakingacasestudyinmetastatichormonerefractoryprostatecancer AT bujkiewiczsylwia bayesianmultiparameterevidencesynthesistoinformdecisionmakingacasestudyinmetastatichormonerefractoryprostatecancer |